Syphilis in Pregnancy

6/19/22, 4:34 PM 4794
Official reprint from UpToDate®

www.uptodate.com © 2022 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
Syphilis in pregnancy
Authors: Errol R Norwitz, MD, PhD, MBA, Charles B Hicks, MD
Section Editors: Charles J Lockwood, MD, MHCM, Jeanne Marrazzo, MD, MPH, FACP, FIDSA
Deputy Editors: Vanessa A Barss, MD, FACOG, Jennifer Mitty, MD, MPH
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: May 2022. | This topic last updated: May 03, 2022.
INTRODUCTION
Syphilis is a systemic infection caused by the spirochete Treponema pallidum. Infection is of

particular concern during pregnancy because of the risk of transplacental transmission to the
fetus. Congenital infection can be associated with several adverse outcomes, including perinatal
death.
Issues related to syphilis during pregnancy will be reviewed here. Syphilis in children and
nonpregnant adults are discussed separately:
● (See "Congenital syphilis: Clinical features and diagnosis".)

● (See "Congenital syphilis: Evaluation, management, and prevention".)
● (See "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients
without HIV".)
● (See "Syphilis: Treatment and monitoring".)
PREVALENCE
● United States – Rates of syphilis infection among pregnant people in the United States
are not available. The rate of primary and secondary syphilis in United States females
overall has been increasing in recent years and more than doubled from 2015 to 2019,
increasing by 179 percent [1]. The highest rates among females were in those 20 to 24
years of age (11.6 cases per 100,000 females) and 25 to 29 years of age (11.8 cases per
100,000 females).
https://www.uptodate.com/contents/4794/print 1/38
6/19/22, 4:34 PM 4794
After a steady decline, the rate of congenital syphilis has also been increasing during this
time period, corresponding to the increasing incidence in reproductive-aged females. In
2020, 2022 cases of congenital syphilis were reported, and 139 (6.9 percent) involved
death related to the infection [2] .
● Globally – Globally, the estimated prevalence of maternal syphilis in 2016 was 0.69
percent (95% CI 0.57-0.81), resulting in a global congenital syphilis rate of 473 (95% CI 385-
561) per 100,000 live births [3].
EPIDEMIOLOGY
Syphilis occurs with equal frequency in males and females worldwide [4], but males are more
commonly infected in the United States. However, the male-to-female rate ratio in the United
States is declining because, although infection rates in both males and females are increasing,
the infection rate in females is increasing faster than that in males [1].
The infection is more common among pregnant people from vulnerable populations. Specific
risk factors include residence in a community with high syphilis rates, misusing drugs, having a
sexually transmitted infection [STI] during pregnancy, having more than one or a new sex
partner, having a sex partner with an STI, having sex in conjunction with drug use or
transactional sex, entering prenatal care during the second trimester or later or no prenatal
care, being incarcerated or having a partner who is incarcerated, or having unstable housing or
homelessness [5,6]. However, in one study, approximately 50 percent of pregnant people with
syphilis in the United States had none of 16 traditional risk factors for the disease [6].
The epidemiology of congenital syphilis is reviewed in more detail separately. (See "Congenital
syphilis: Clinical features and diagnosis", section on 'Epidemiology'.)
MATERNAL ACQUISITION OF INFECTION
Sexual transmission requires exposure to open lesions in which microorganisms are present.
The spirochetes pass from the lesion across intact non-keratinized epithelium or abraded skin
into the new host. The efficiency of sexual (horizontal) transmission is estimated to be
approximately 30 percent [7]. The incubation period varies from 10 to 90 days (average
approximately three weeks); larger inocula shorten this incubation period [8]. (See "Syphilis:
Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on
'Transmission'.)
6/19/22, 4:34 PM 4794
MATERNAL CLINICAL MANIFESTATIONS
The clinical manifestations of syphilis are not affected by the pregnant state. (See "Syphilis:
Epidemiology, pathophysiology, and clinical manifestations in patients without HIV".)
MATERNAL SCREENING
Universal antepartum screening is widely recommended because screening followed by

treatment with appropriate antibiotics usually prevents adverse maternal and offspring
outcomes ( algorithm 1) [9-11]. Screening is performed using a serologic test; either a
treponemal or nontreponemal test can be used. All of the tests have similar sensitivity and
specificity, so preference is based on other factors (eg, cost, time, personnel requirements). (See
'Serologic testing' below.)
Candidates and timing of initial and repeat screening
● All pregnant people: screen at the first prenatal encounter

● Pregnant people at high risk of infection: repeat screening at 28 to 32 weeks and at
delivery
● Pregnant people who have not been screened in pregnancy or who give birth to a stillborn
after 20 weeks of gestation: screen at delivery
The United States Centers for Disease Control and Prevention (CDC) and many other global and
national organizations recommend screening all pregnant people for syphilis at the first
prenatal visit [12-17]. The cost and morbidity associated with screening for syphilis are low and
the benefit of detecting and treating the disease is high for both mother and child. Universal
screening for syphilis has the advantage of removing the stigma of testing since all pregnant
people are screened, not just those considered to be at higher risk. The major harm of
screening is the anxiety associated with a false-positive result [18,19]. (See 'False-positive
serologic tests in pregnancy' below.)
Routinely rescreening all pregnant people in the third trimester and/or at delivery is not cost-
effective [20]. For pregnant people who are at high risk for acquiring syphilis (see
'Epidemiology' above), the CDC recommends repeating screening during the third trimester at
28 to 32 weeks and again at delivery [21]. Local prevalence rates are available from the CDC,
which annually publishes prevalence rates in the United States based on variables such as
county, sex, age group, ethnicity, and sexual behavior, but not pregnancy status.
6/19/22, 4:34 PM 4794
Opportunities for screening outside of traditional prenatal care — Screening for syphilis
should be considered when a pregnancy is diagnosed in a nonobstetric setting, such as a drug
treatment center, prison, emergency medicine department, or outreach program, given that
pregnant people with syphilis are less likely to receive prenatal care.
Rapid point of care tests are less accurate than standard nontreponemal and treponemal tests
[22], but can be helpful in guiding initial treatment decisions in patients in whom return for
follow-up is uncertain and thus reduce the risk of adverse outcomes from congenital syphilis
[23]. (See "Syphilis: Screening and diagnostic testing", section on 'Rapid serologic tests'.)
Concurrent HIV screening — All pregnant people should be offered HIV counseling and
testing using an opt-out approach [24]. HIV testing is strongly recommended for those known
to have a sexually transmitted disease, such as syphilis, due to the high risk of coexistent
disease. HIV testing should be repeated at the time of repeat syphilis screening. (See "Prenatal
care: Initial assessment", section on 'HIV'.)
DIAGNOSIS
Serologic testing — For most patients, the diagnosis of syphilis is made through serologic
testing of blood specimens. Methods that detect the organism directly (eg, darkfield
microscopy) are not generally available.
Serologic testing to diagnose syphilis should include the use of both treponemal and
nontreponemal tests:
● Specific treponemal tests include fluorescent treponemal antibody absorption (FTA-ABS),

microhemagglutination test for antibodies to T. pallidum (MHA-TP), T. pallidum particle
agglutination assay (TPPA), T. pallidum enzyme immunoassay (TP-EIA), and
chemiluminescence immunoassay (CIA). The TP-EIA is a commonly performed treponemal
test because it allows inexpensive volume testing of blood samples with minimal time
requirements for laboratory personnel.
● Nontreponemal tests include Rapid Plasma Reagin (RPR), Venereal Disease Research
Laboratory (VDRL), and Toluidine Red Unheated Serum Test (TRUST). The RPR and VDRL
are the most commonly performed nontreponemal tests.
Either test can be used as the initial screening test, depending on the preference of the
laboratory performing the test ( algorithm 1). Most laboratories use a testing strategy that
screens with a treponemal assay (most often an enzyme immunoassay) and then use a
6/19/22, 4:34 PM 4794
nontreponemal test (RPR or VDRL) for confirmatory testing. Confirmatory testing is necessary
due to the potential for a false-positive screening test result. (See "Syphilis: Screening and
diagnostic testing", section on 'Serologic testing algorithms'.)
The diagnostic interpretation of syphilis serology, including interpretation of testing in patients

with prior syphilis, is the same as in nonpregnant individuals. As an example, in a patient
without prior syphilis, a diagnosis of syphilis is made when both treponemal tests and
nontreponemal tests are reactive. A more detailed discussion of how to interpret serologic
testing is presented elsewhere. (See "Syphilis: Screening and diagnostic testing", section on
'Interpretation of serologic testing'.)
False-positive serologic tests in pregnancy
● Prevalence – Biologic false-positive nontreponemal and treponemal results are relatively

common in pregnant people. For example, in one study, 31 percent of pregnant people
with a positive VDRL had a false-positive result [25]. When treponemal tests are used as
the initial screening test, 47 to 88 percent of pregnant people with positive TP-EIAs or CIAs
have a false-positive result [26-31].
● Patient evaluation during pregnancy – Given the high risk of a false-positive test, testing
algorithms should include confirmatory testing of an initial positive test ( algorithm 1)
[32]. When an initial treponemal screening test is positive but the follow-up
nontreponemal result is negative, treponemal reflexive testing is performed. If reflex
testing is also positive, the negative nontreponemal test may be secondary to a prozone
effect. (See "Syphilis: Screening and diagnostic testing", section on 'Prozone reaction'.)
A positive (reactive) low titer nontreponemal screening test can be considered a transient
biologic false-positive result due to pregnancy if the follow-up treponemal test is negative
and the patient is asymptomatic and at low risk of acute syphilis. False-positive
nontreponemal test results can also be related to an acute event, such as an acute febrile
illness or recent immunization. Test abnormalities attributed to these conditions are
usually transitory, typically lasting for six months or less. In addition to pregnancy,
conditions associated with a false-positive CIA treponemal test include advanced age (>50
years), tumor, dialysis, and autoimmune disease [27], while a false-positive EIA has been
associated with advanced age (≥40 years) [29].
● Follow-up after delivery – All patients with biologic false-positives attributed to

pregnancy or another transient event should undergo follow-up testing at least four to six
weeks after giving birth. If the discordancy persists, then the need for further evaluation
can be determined on a case-by-case basis, taking into account factors such as symptoms
6/19/22, 4:34 PM 4794
(eg, signs/symptoms of autoimmune disease) and risk of syphilis infection [26-30,32]. (See
"Syphilis: Screening and diagnostic testing", section on 'Positive nontreponemal/negative
treponemal'.)
STAGING
The stage of syphilis is clinically important because it impacts the treatment regimen and the
risk of vertical transmission. (See 'Vertical transmission' below.) Patients whose screening test
for syphilis is positive should be staged based on history and physical examination. Each stage
of syphilis has characteristic clinical findings that are not altered by pregnancy. A synopsis is
provided below and in the table ( table 1). A detailed discussion of staging, including
photographs of lesions, can be found separately. (See "Syphilis: Epidemiology, pathophysiology,
and clinical manifestations in patients without HIV", section on 'Clinical manifestations' and
"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV",
section on 'Stages of disease'.)
● Primary syphilis — When symptomatic, the first manifestation of syphilis is a skin lesion
that may be macular initially but typically evolves into a painless papule at the site of
inoculation. This soon ulcerates to produce the classic chancre(s) of primary syphilis, a 1 to
2 centimeter painless ulcer with a raised, indurated margin that may be genital or
extragenital. The ulcer is associated with mild to moderate regional lymphadenopathy
that may be bilateral. Chancres heal spontaneously within three to six weeks, even in the
absence of treatment. The primary stage of syphilis may not be noticed if the lesion is on
the vaginal or cervical epithelium. (See "Syphilis: Epidemiology, pathophysiology, and
clinical manifestations in patients without HIV", section on 'Primary syphilis (chancre)'.)
● Secondary syphilis — Secondary syphilis is a disseminated systemic process that occurs

in approximately 25 percent of untreated patients, usually beginning six weeks to six
months after the appearance of the chancre of primary syphilis. A generalized
maculopapular skin rash involving the palms and soles and mucous membranes is
characteristic of this stage of the infection. Generalized lymphadenopathy may
accompany the rash. Additional clinical features may include fever, pharyngitis, weight
loss, and condylomata lata. Although spirochetes can be found in the cerebrospinal fluid
(CSF) of around 40 to 50 percent of patients with early syphilis [33], neurologic
manifestations are uncommon. The rash of secondary syphilis typically resolves
spontaneously within two to six weeks. (See "Syphilis: Epidemiology, pathophysiology, and
clinical manifestations in patients without HIV", section on 'Secondary syphilis'.)
6/19/22, 4:34 PM 4794
● Latent syphilis — In the United States, latent syphilis is defined as "early latent" when it is
possible to document a nonreactive syphilis serology within the past year or a history of
symptoms of early syphilis within the past year. Otherwise, the disease is considered "late
latent". Latent syphilis is by definition asymptomatic. If untreated, a small proportion of
patients will develop signs and symptoms of secondary or late syphilis, but many will
remain asymptomatic. People with latent syphilis can transmit the infection to sexual
partners, or the fetus; however, this is considerably less common in late latent syphilis.
(See "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients
without HIV", section on 'Latent syphilis (asymptomatic)' and 'Vertical transmission' below.)
● Tertiary (late) syphilis — Tertiary syphilis is infrequently diagnosed and is characterized

by slowly progressive signs and symptoms. Clinical manifestations include gumma
formation and cardiovascular disease. Such manifestations usually develop 5 to 20 years
after the disease has become latent. (See "Syphilis: Epidemiology, pathophysiology, and
clinical manifestations in patients without HIV", section on 'Late syphilis'.)
● Neurosyphilis — Early in the course of syphilis infection, T. pallidum can enter the central
nervous system and subsequently produce a variety of signs and symptoms during both
early and late syphilis. Neurosyphilis is described in detail separately. (See
"Neurosyphilis".)
MATERNAL TREATMENT
Treatment setting — The authors administer treatment for syphilis in an outpatient setting,
and counsel patients about potential side effects and when to contact their provider. Others
may choose to administer the first dose of penicillin in a labor and delivery unit with continuous
fetal monitoring for at least 24 hours in pregnancies that have reached a gestational age when
intervention would be considered in case of Jarisch-Herxheimer reaction and its potential
sequelae (eg, preterm labor, nonreassuring fetal heart rate pattern) [5]. There is no consensus
regarding the best approach; both are acceptable. (See 'Potential complications of treatment:
Jarisch-Herxheimer reaction' below.)
Preferred regimen: penicillin
Key principles
● Penicillin G benzathine is the standard for the treatment of syphilis in both pregnant
and nonpregnant individuals. No clinically relevant penicillin-resistant strains of T. pallidum
have been identified to date. Penicillin G benzathine therapy is effective for treating
6/19/22, 4:34 PM 4794
maternal disease, preventing transmission to the fetus, and treating established fetal
disease.
● Pregnant people with penicillin allergy should be desensitized and treated with
penicillin G benzathine because penicillin G benzathine is considered the only appropriate
treatment of syphilis during pregnancy. Desensitization may be performed in the
outpatient or inpatient setting, depending on the severity of the past reaction and
available resources. (See "Rapid drug desensitization for immediate hypersensitivity
reactions", section on 'Risk stratification' and "Rapid drug desensitization for immediate
hypersensitivity reactions", section on 'Setting and staffing'.)
● The appropriate penicillin G benzathine regimen depends on the stage of disease (

table 2). The pregnant state does not affect the maternal response to treatment. (See
'Patients with immediate type allergic reactions to penicillin' below.)
● Bicillin L-A must be distinguished from Bicillin C-R – Penicillin G benzathine (long-acting
intramuscular) is marketed under the trade name Bicillin L-A. This agent should only be
given via the intramuscular route since intravenous administration has been associated
with cardiopulmonary arrest and death.
Bicillin L-A must be distinguished from Bicillin C-R (which contains equal concentrations of
intermediate-acting procaine and long-acting benzathine penicillin) and should not be
used to treat patients with syphilis.
Treatment of primary, secondary, or early latent disease and post-exposure prophylaxis
● A single dose of penicillin G benzathine 2.4 million units intramuscularly is appropriate for
patients with primary, secondary, or early latent disease and for post-exposure
prophylaxis after sexual contact with a partner with known or suspected syphilis (
table 2) (see 'Staging' above).
Some clinicians administer an additional dose of penicillin G benzathine 2.4 million units one
week after the first dose to patients with primary, secondary, or early latent disease [5], based
in part on evidence of efficacy [34-36] and on pharmacokinetic data of altered penicillin levels in
pregnant people [37,38]. There is no harm to giving a second dose, but it has not been
recommended in guidelines from national organizations because the value of a second dose
has not been evaluated in a randomized trial and there have been shortages of penicillin G
benzathine in some countries. A second dose of penicillin is not administered to nonpregnant
patients with primary, secondary, or early latent disease. (See "Syphilis: Treatment and
monitoring", section on 'Treatment of early syphilis'.)
6/19/22, 4:34 PM 4794
Treatment of late latent and tertiary disease
● Three doses of penicillin G benzathine 2.4 million units intramuscularly at weekly intervals
are recommended for late latent and tertiary syphilis ( table 2).
Pregnant people whose scheduled dose is delayed by >9 days should repeat the full course of
therapy [21]. (See "Syphilis: Treatment and monitoring", section on 'Treatment of late syphilis'.)
If an asymptomatic patient with suspected latent syphilis was previously treated for syphilis but
receipt of an appropriate treatment regimen cannot be verified, then the full three-dose
penicillin regimen recommended for late latent syphilis should be administered. Diagnosis of
treatment failure is discussed below. (See 'Interpretation of response to therapy and diagnosis
of treatment failure' below.)
Treatment of neurosyphilis — Treatment of neurosyphilis is parenteral and typically requires

inpatient administration ( table 2). (See "Syphilis: Treatment and monitoring", section on
'Treatment of neurosyphilis'.)
Patients with immediate type allergic reactions to penicillin — For pregnant people with
syphilis and a history of an immediate type allergic reaction to penicillin, the only satisfactory
treatment is desensitization followed by penicillin therapy [21].
Penicillin allergy is reported by 5 to 10 percent of pregnant people [39]; however, serious

allergic reactions to penicillin are rare. It is important to verify the history of "allergy," since the
patient may incorrectly assume a nonallergic side effect (eg, nausea or vomiting) to be allergic
in origin. The major symptoms of concern are immunoglobulin E (IgE)-mediated (immediate)
responses, such as urticaria, angioedema or anaphylaxis with airway obstruction,
bronchospasm or hypotension ( table 3).
Referral — Patients who report symptoms suggestive of a past immediate allergy to a

penicillin should be evaluated with penicillin skin testing, if possible. In most cases, this involves
referral to an allergist, as skin testing requires some expertise to perform and interpret. In
addition, allergists can perform rapid drug desensitization protocols if appropriate. (See
'Desensitization' below.)
Many patients may give a vague history of a mild reaction, such as rash, which is difficult to
classify with any precision. We suggest consulting an allergist in such cases, but if an allergist is
not available and the clinician believes the risk of a significant reaction is minimal, a test dose or
graded challenge may be performed. Test dosing is discussed elsewhere. (See "An approach to
the patient with drug allergy", section on 'Graded challenge'.)
6/19/22, 4:34 PM 4794
Skin testing — Penicillin skin testing takes approximately one hour to perform and can
determine if the patient has an immediate penicillin allergy.
Individuals who had a true IgE-mediated reaction to penicillin in the distant past with no
reexposure may lose their sensitivity over time. Approximately 80 percent of patients with a
history of IgE-mediated penicillin allergy that occurred ≥10 years in the past will now have a
negative skin test and can safely take penicillin. (See "Penicillin allergy: Immediate reactions",
section on 'Penicillin skin testing' and "Penicillin allergy: Immediate reactions", section on 'Time
elapsed since the reaction'.)
● Positive test – Pregnant people with a positive skin test are at significant risk of a reaction
to penicillin; two-thirds develop some allergic symptoms and a subset of those will have a
life-threatening anaphylactic reaction [39]. Penicillin desensitization is recommended for
pregnant people with a positive skin test who require penicillin therapy. (See "Penicillin
allergy: Immediate reactions", section on 'Desensitization'.)
● Negative test – Pregnant people with negative skin test results are at no greater risk for a
reaction to penicillin than the general population and can receive the drug. However, the
first dose should be given under medical supervision because the negative predictive
value of skin testing, while high, is not 100 percent.
Desensitization — It is strongly recommended that desensitizations be performed by

allergy specialists.
Penicillin desensitization involves exposing the patient to a small amount of penicillin and
gradually increasing the dose until an effective level is reached, followed by the appropriate
therapeutic penicillin regimen. Penicillin desensitization can be achieved either orally or
intravenously. Oral desensitization is simpler and safer. The procedure requires approximately
four hours to accomplish and requires close patient monitoring. Most adverse reactions can be
managed without discontinuation of the desensitization protocol.
Desensitizations are usually performed in the hospital and often in the intensive care setting
because it is critical to have the staffing and equipment available to manage anaphylaxis.
However, oral desensitization to penicillin has been performed by allergy specialists in the
outpatient setting, with one-on-one nursing and intravenous access.
Protocols for intravenous desensitizations are reviewed separately. (See "Penicillin allergy:
Immediate reactions", section on 'Desensitization' and "Rapid drug desensitization for
immediate hypersensitivity reactions".)
6/19/22, 4:34 PM 4794
Role of nonpenicillin regimens — During pregnancy, nonpenicillin antibiotic regimens used

for syphilis treatment in males and nonpregnant females are either contraindicated (eg,
tetracycline), lack sufficient data regarding efficacy (eg, ceftriaxone), or do not cross the
placental barrier completely so the fetus is not effectively treated (eg, erythromycin,
azithromycin). Therefore, they are not recommended for pregnant people. Nonpenicillin
regimens should only be considered when penicillin cannot be obtained or for penicillin-
allergic patients when penicillin desensitization is not possible. (See 'Patients with
immediate type allergic reactions to penicillin' above.)
● World Health Organization (WHO) regimens – In parts of the world where penicillin
desensitization is not possible [40]:
• For nonpenicillin treatment of early syphilis (ie, primary, secondary, or latent <2 years
[WHO definition]) in pregnancy, administer one of the following alternative regimens:
- Erythromycin 500 mg orally four times daily for 14 days, or

- Ceftriaxone 1 g intramuscularly once daily for 10 to 14 days, or
- Azithromycin 2 g once orally (when local susceptibility to azithromycin is likely)
• For nonpenicillin treatment of late syphilis, administer erythromycin 500 mg orally four
times daily for 30 days.
• Infants born to individuals who were treated during pregnancy with nonpenicillin
regimens should receive penicillin treatment because erythromycin and azithromycin
do not cross the placental barrier completely so the fetus is not effectively treated.
- Aqueous benzyl penicillin 100,000 to 150,000 U/kg/day intravenously for 10 to 15

days, or
- Procaine penicillin 50,000 U/kg/day single dose intramuscularly for 10 to 15 days
A small study in China evaluated the use of ceftriaxone for treatment of early syphilis in 11
pregnant people with a history of penicillin allergy [41]. Preliminary results were encouraging,
RPR titers fell and there were no clinical manifestations of congenital syphilis in the infants. A
large scale trial of this treatment strategy is planned as an alternative to desensitization. Until
the results of such trials are available, penicillin desensitization followed by penicillin treatment
should be regarded as "standard of care" for the management of penicillin-allergic pregnant
people with syphilis.
6/19/22, 4:34 PM 4794
POTENTIAL COMPLICATIONS OF TREATMENT: JARISCH-HERXHEIMER

REACTION
Treatment of syphilis may precipitate the Jarisch-Herxheimer reaction. The risk of occurrence of
Jarisch-Herxheimer reaction is not a contraindication to syphilis treatment. However, all patients
should be counseled about the risks and clinical features of this febrile reaction, and told to
contact their provider if symptoms occur.
● Signs and symptoms – Clinical manifestations include an acute febrile reaction

accompanied by headache, myalgia, rash, and hypotension [42]. The reaction begins
within one to two hours of treatment, peaks at eight hours, and typically resolves within
24 to 48 hours. In one series, 15 out of 33 pregnant people treated for syphilis on a high
risk pregnancy unit at Parkland Hospital had a Jarisch-Herxheimer reaction, including 3
out of 3 with primary syphilis, 12 out of 20 with secondary syphilis, and 0 out of 10 with
latent syphilis [42]. The reaction may be more common in people with HIV.
Management is supportive care (eg, antipyretics, intravenous fluids).
The clinical findings are thought to result from the release of large amounts of treponemal
lipopolysaccharide from dying spirochetes and an increase in circulating cytokine levels
(tumor necrosis factor alpha [TNF-alpha], interleukin-6, interleukin-8).
● Complications – The Jarisch-Herxheimer reaction may precipitate uterine contractions,

preterm labor, and/or nonreassuring fetal heart rate tracings in pregnant people treated
in the second half of pregnancy [42,43]. Patients should report symptoms of labor or
decreased fetal activity to their provider immediately; evaluation and treatment are
according to usual obstetric standards.
● Role of premedication – The authors do not premedicate patients. Premedication with

corticosteroids [44] or TNF-alpha antibodies [45,46] appears to prevent the reaction, but is
not widely used given limited data of the relative risks and benefits of this approach, with
no data in pregnant people. In a study of 22 nonpregnant patients with primary syphilis
treated with penicillin for three days, 15 patients were given penicillin alone while the
other 7 received 20, 40, or 60 mg of oral prednisolone on the first and second day of
antibiotic administration [44]. Jarisch-Herxheimer reactions (defined as temperature
≥38°C) occurred more frequently in the control group (93 versus 12 percent) and in no
patient who received 60 mg of prednisolone. Nonfebrile manifestations of the reaction
were not evaluated.
6/19/22, 4:34 PM 4794
Premedication with acetaminophen or meptazinol may reduce the severity or duration of

symptoms, but the reaction itself is not prevented [47]; premedication with pentoxifylline
has not been effective [48].
POST-TREATMENT MATERNAL FOLLOW-UP
Clinical follow-up — Patients with early syphilis should be assessed clinically for resolution of
symptoms (eg, rash, ulcer). However, for patients with late stage cardiovascular or
noncutaneous gummatous disease, a significant change in symptoms is unlikely. Monitoring is
described in detail separately. (See "Syphilis: Treatment and monitoring", section on 'Clinical
assessment'.)
Frequency of nontreponemal titers — Pregnant people treated for early syphilis should have
a nontreponemal titer checked at the time of treatment to establish a baseline against which to
monitor response to treatment, since this titer may differ from that of the initial diagnostic test
due to elapsed time between diagnosis and initiation of therapy. The subsequent frequency of
monitoring is the same as in nonpregnant patients and depends upon the stage of disease and
presence of HIV coinfection.
When monitoring nontreponemal titers, the same test should be performed each time (ie, serial
rapid plasma antigen or serial Venereal Disease Research Laboratory) and ideally at the same
laboratory. (See "Syphilis: Treatment and monitoring".)
Interpretation of response to therapy and diagnosis of treatment failure
● A fourfold increase in the nontreponemal titer after treatment is evidence of treatment

failure.
● A fourfold decline in the titer, equivalent to a change of two dilutions (eg, from 1:16 to 1:4
or from 1:32 to 1:8), is considered to be an acceptable response to syphilis therapy.
A decline in maternal nontreponemal serologic titers following treatment does not

guarantee that fetal treatment has been adequate. Thus, neonates should be evaluated
for congenital syphilis after delivery. (See "Congenital syphilis: Evaluation, management,
and prevention" and "Congenital syphilis: Clinical features and diagnosis".)
There is wide patient-to-patient variability in the rate of decline in nontreponemal titers, which
can be influenced by factors such as previous episodes of syphilis, HIV infection, stage of
syphilis, and the level of the titer at the time of diagnosis. If the diagnostic titer is low (eg, 1:4), it
is common for the rate of decline to be slower than if the diagnostic titer is high (eg, 1:128). In
6/19/22, 4:34 PM 4794
nonpregnant patients, an adequate response to therapy is expected by 12 months for patients

with early syphilis and 24 months for patients with late syphilis, but the authors are willing to
avoid retreatment as long as the titer is declining, even if the pace is slower than expected.
However, in pregnancy, it is probably prudent to err on the side of overtreatment for early or
late syphilis, so retreatment is reasonable if a fourfold decline from pretreatment titer has not
occurred by six months.
Seroreversion and serofast states — The loss of antibodies over time (seroreversion) in a
patient who has been treated for syphilis is considered consistent with clinical cure. The
majority of patients who are treated for syphilis will experience seroreversion over time. Issues
regarding the serofast state are reviewed separately. (See "Syphilis: Treatment and monitoring",
section on 'Serologic testing' and "Syphilis: Treatment and monitoring", section on
'Management of treatment failure'.)
POTENTIAL ADVERSE PREGNANCY OUTCOMES
Pregnancies complicated by syphilis are at increased risk of several adverse outcomes from
placental and fetal infection [33,49-53]. Maternal treatment reduces the risk of adverse
outcomes, but preterm labor can be precipitated by the Jarisch-Herxheimer reaction (see
'Potential complications of treatment: Jarisch-Herxheimer reaction' above). Adverse outcomes
include:
● Pregnancy loss
● Preterm birth
● Stillbirth
● Impaired fetal growth
● Congenital infection ( table 4)
● Neonatal mortality
VERTICAL TRANSMISSION
Inadequate maternal screening and/or inadequate maternal treatment can result in congenital
syphilis. Screening failures occur primarily among pregnant people who do not receive prenatal
care or have late entry into prenatal care and in high-risk patients who are not rescreened in
the third trimester and at delivery [18,54].
Pathogenesis of congenital infection — T. pallidum readily infects the placenta. Transplacental

transmission to the fetus can occur from approximately the 9th to 10th week of gestation [55]
6/19/22, 4:34 PM 4794
and at any stage of maternal disease. Importantly, the manifestations of congenital infection
are influenced by the gestational age, state of maternal syphilis, maternal treatment, and
immunological response of the fetus.
Fetal abnormalities result from a robust inflammatory response to T. pallidum; thus, they are
most pronounced after 20 weeks of gestation since the fetal immunologic response is poorly
developed in the first half of pregnancy [5]. After the placenta is infected, transplacental
passage of spirochetes to the fetal circulation leads to fetal hepatic infection and dysfunction,
followed by amniotic fluid infection, fetal hematologic abnormalities (anemia,
thrombocytopenia), ascites, hydrops, and fetal immunoglobulin M (IgM) production [56].
Hepatomegaly is thought to be caused by inflammation, extramedullary hematopoiesis, and
hepatic congestion [5].
Neonates can also become infected during birth from contact with maternal secretions or blood
containing spirochetes.
Factors influencing frequency of vertical transmission — In two systematic reviews, 15 and

36 percent of infants of mothers with untreated syphilis had clinical evidence of congenital
syphilis [57,58]. Factors that increase the risk of congenital infection include:
● Early stage syphilis – The risk of congenital infection is extremely high in the first four
years after maternal acquisition of infection, when spirochetemia is common in the
absence of treatment [59-61]. When looked at by stage, the risk of congenital infection in
term infants has been reported to be 50 percent for primary and secondary untreated
syphilis, 40 percent for early latent untreated syphilis, and 10 percent for late untreated
syphilis [62]. When looked at by baseline titer, the risk of congenital syphilis in offspring of
patients with nontreponemal titer ≥8 versus <8 was 26 and 4 percent, respectively, in one
systematic review [58].
● Maternal acquisition of infection later rather than earlier in gestation – The

frequency of vertical transmission increases with increasing gestational age at acquisition
of maternal infection.
● Failure to appropriately identify and treat maternal infection – Reviews of congenital

syphilis cases generally reveal that most could have been prevented [63]. The majority of
cases occurred because of:
• Lack of maternal screening (often because of lack of prenatal care, sometimes because
high-risk patients may not be identified if providers are uncomfortable asking
questions about sexual behavior)
6/19/22, 4:34 PM 4794
• Lack of third-trimester rescreening in high-risk patients
• Lack of screening at delivery in high-risk patients and pregnant people who did not
receive prenatal care
• Lack of appropriate follow-up and treatment
Globally, many undetected maternal cases are also due to lack of adequate antenatal care
services. Although 88 percent of pregnant people globally had at least one prenatal care
visit, among syphilis-infected mothers, only 51 percent of those who had a prenatal visit
were adequately treated [3]. Pregnant people who received some prenatal care but were
not diagnosed or diagnosed but not treated accounted for 74 percent of the global
congenital syphilis burden. Point-of-care testing and same-day treatment could be
effective in antenatal care settings where loss to follow-up for test results and treatment is
common.
In New York City, 68 individuals gave birth to an infant with congenital syphilis in 2010 to
2016 [64]. Of these individuals, approximately one-third did not receive prenatal care or a
syphilis test ≥45 days before delivery; another one-third had a time-appropriate,
nonreactive test at the first prenatal visit and subsequently acquired syphilis during
pregnancy, but it was not diagnosed in most of this group because they did not have
repeat testing at 28 to 32 weeks; and many of the remaining individuals had a reactive
syphilis test ≥45 days before delivery but had inadequate maternal treatment because
treatment was initiated too late or not at all.
Prenatal (fetal) diagnosis — Fetal infection should be suspected if there are characteristic
findings on ultrasound examination after 20 weeks of gestation in a pregnant person with
untreated or inadequately treated syphilis. Before 18 to 20 weeks, fetal abnormalities are not
usually seen because of fetal immunologic immaturity. (See 'Pathogenesis of congenital
infection' above.)
Findings on ultrasound are nonspecific and included the following in one review [65]:
● Hepatomegaly, defined as liver length >95th percentile for gestational age (83 percent)
● Anemia, based on Doppler middle cerebral artery peak systolic velocity >1.5 multiples of
the median (38 percent)
● Placentomegaly, defined as placental thickness >2 standard deviations above mean for
gestational age (34 percent)
6/19/22, 4:34 PM 4794
● Growth restriction (14 percent)
● Hydrops (12 percent)
• Skin edema 7 percent, pericardial effusion 2 percent, ascites 19 percent
● Polyhydramnios (11 percent), oligohydramnios (9 percent)
Hepatomegaly and placentomegaly are early findings. Anemia, ascites, and hydrops occur later
in the course of infection.
An abnormal ultrasound is not diagnostic of fetal infection and a normal ultrasound does not
exclude fetal infection. In one series, congenital syphilis was diagnosed in 39 percent of infants
of seropositive mothers who had a pretreatment fetal ultrasound with one or more of the
above findings and in 12 percent of infants when the ultrasound examination was normal [66].
Some manifestations of congenital disease are subtle and/or not seen on prenatal ultrasound
examination (eg, ocular and osseous abnormalities). (See "Congenital syphilis: Clinical features
and diagnosis", section on 'Early congenital syphilis' and "Congenital syphilis: Evaluation,
management, and prevention".)
Diagnostic testing of amniotic fluid or fetal blood definitively establishes intrauterine infection,
but invasive procedures to obtain these specimens can be associated with complications, do
not change management, and thus are not recommended. Potential fetal laboratory
manifestations of infection were illustrated in a series of 24 pregnant people with primary,
secondary, or early latent syphilis diagnosed after 24 weeks of gestation who underwent
funipuncture [56]. The following abnormalities were noted: abnormal liver chemistries (88
percent), thrombocytopenia (35 percent), anemia (26 percent), and positive fetal antitreponemal
IgM (13 percent).
Fetal treatment and treatment failure — Maternal penicillin treatment is curative for fetal
infection in most cases. Although fetal anemia is one of the adverse sequelae of congenital
infection, intrauterine transfusion is rarely necessary as appropriate treatment of maternal
infection generally reverses the anemia [5].
Congenital infection has been diagnosed in 1 to 2 percent of offspring of mothers adequately

treated during pregnancy compared with 70 to 100 percent of offspring of untreated mothers.
The WHO estimates that treatment reduces early fetal deaths or stillbirths by 82 percent,
preterm or low birth weight by 65 percent, neonatal deaths by 80 percent, and clinical disease
in infants by 97 percent [67].
6/19/22, 4:34 PM 4794
In an observational series of 43 treatment failures, the following characteristics were more

likely in adequately treated patients who went on to have congenitally infected infants [61]:
● High nontreponemal titer at treatment and delivery

● Birth ≤36 weeks
● Early stage infection
● Short interval (≤30 days) between treatment and giving birth
The authors hypothesized that high treponemal load, altered penicillin pharmacokinetics in
pregnancy, and inadequate time for fetal therapeutic response may have accounted for the
treatment failures.
Newborn evaluation and treatment — The clinical manifestations, diagnosis, treatment, and
prognosis of congenital syphilis in the neonate are discussed separately. (See "Congenital
syphilis: Evaluation, management, and prevention" and "Congenital syphilis: Clinical features
and diagnosis".)
PREGNANCY MANAGEMENT
Pregnancies in people with syphilis should be comanaged by obstetric and infectious disease
specialists.
Ultrasound examination — At least one ultrasound examination after 20 weeks of gestation

should be performed to look for signs of congenital infection. In pregnancies with a
presumptive sonographic diagnosis of congenital syphilis, ultrasound examinations should be
performed every one or two weeks to assess fetal well-being and the fetal response to
treatment.
With successful fetal treatment, middle cerebral arterial Doppler abnormalities, ascites, and
polyhydramnios resolve first (usually within approximately one month), followed by
placentomegaly, and lastly hepatomegaly. Hepatomegaly can take months to resolve after
maternal treatment [66].
Delivery issues
● Late preterm delivery for neonatal treatment is indicated when there is a high risk of fetal
treatment failure (eg, progressive worsening signs of congenital syphilis on ultrasound
examination, hydrops) [5,56].
6/19/22, 4:34 PM 4794
● If the patient first presents for pregnancy care when they are in labor and their
nontreponemal or treponemal test is positive, maternal evaluation and treatment for
syphilis are performed as described above; intrapartum care and procedures are not
impacted.
● At delivery, pediatric providers should be notified about maternal syphilis stage and
treatment, and fetal ultrasound findings. (See "Congenital syphilis: Evaluation,
management, and prevention" and "Congenital syphilis: Clinical features and diagnosis".)
Placenta — The placenta/fetal membranes should be sent for histopathologic examination. The
pathologist should be notified about maternal syphilis stage and treatment.
The placenta in people with untreated syphilis is typically large and edematous. Characteristic
placental findings include ( picture 1):
● Hydrops placentalis
● Chronic villitis (plasma cells, mixed acute and chronic infiltrate)
● Perivillous fibrous proliferation (onion skin vessels)
● Normoblastemia
● Necrotizing funisitis
● Acute chorioamnionitis
● Plasma cell deciduitis
These pathological changes can adversely affect fetoplacental exchange of oxygen and
nutrients, which may account, at least in part, for some adverse fetal outcomes [5].
Silver stain should reveal the spirochetes, but they are often very difficult to identify. The best
yield is often in the decidua basalis or capsularis where there are plasma cells or, in cases of
fetal death, in the vitreous.
SOCIETY GUIDELINE LINKS
Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Sexually transmitted
infections".)
INFORMATION FOR PATIENTS
6/19/22, 4:34 PM 4794
UpToDate offers two types of patient education materials, "The Basics" and "Beyond the
Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade
reading level, and they answer the four or five key questions a patient might have about a given
condition. These articles are best for patients who want a general overview and who prefer
short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more
sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading
level and are best for patients who want in-depth information and are comfortable with some
medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print
or e-mail these topics to your patients. (You can also locate patient education articles on a
variety of subjects by searching on "patient info" and the keyword(s) of interest.)
● Basics topic (see "Patient education: Congenital syphilis (The Basics)")
SUMMARY AND RECOMMENDATIONS
● Clinical findings – Each stage of syphilis has characteristic maternal clinical features that
are not altered by pregnancy ( table 1). (See 'Staging' above.)
● Diagnosis – Diagnostic evaluation for maternal syphilis is the same in pregnant and
nonpregnant individuals. A maternal diagnosis of syphilis is made when both
nontreponemal and treponemal tests are reactive. (See 'Diagnosis' above.)
● Screening – We recommend screening pregnant people for syphilis (Grade 1B) (See
'Maternal screening' above.).
• All pregnant people: screen at the first prenatal encounter
• Pregnant people at high risk of infection: repeat screening at 28 to 32 weeks and at

delivery
• Pregnant people who have not been screened in pregnancy or who deliver a stillborn
after 20 weeks of gestation: screen at delivery
● False-positive screening tests – False-positive screening tests may be more common in

the setting of pregnancy. Confirmatory testing must be performed ( algorithm 1). (See
'False-positive serologic tests in pregnancy' above.)
● Treatment – Penicillin G benzathine is the standard for the treatment of syphilis
6/19/22, 4:34 PM 4794
• Penicillin G benzathine therapy is effective for treating maternal disease, preventing

transmission to the fetus, and treating established fetal disease. The long-acting
intramuscular formulation must be used (Bicillin L-A); Bicillin C-R (which contains equal
concentrations of intermediate-acting procaine and long-acting benzathine penicillin)
should not be used to treat patients with syphilis. (See 'Maternal treatment' above.)
• The appropriate penicillin G benzathine regimen depends on the stage of disease (

table 2).
- Primary, secondary, or early latent disease: a single dose of penicillin G

benzathine 2.4 million units intramuscularly. Some clinicians administer an
additional dose of penicillin G benzathine 2.4 million units one week after the first
dose. (See 'Treatment of primary, secondary, or early latent disease and post-
exposure prophylaxis' above.)
- Late latent, tertiary, and disease of unknown duration: three doses of penicillin
G benzathine 2.4 million unit intramuscularly at weekly intervals. If a dose is
missed for more than 14 days, the full three dose course of therapy should be
started again. (See 'Treatment of late latent and tertiary disease' above.)
If an asymptomatic patient with what could be latent syphilis was previously

treated for syphilis but receipt of an appropriate treatment regimen cannot be
verified, the full three-dose penicillin regimen recommended for late latent syphilis
should be administered.
● Desensitization in penicillin allergy – We recommend desensitization for penicillin-

allergic pregnant patients followed by penicillin G benzathine therapy (Grade 1B).
Alternative drugs are not as safe for the pregnant person or fetus or not as effective for
prevention of congenital syphilis. (See 'Patients with immediate type allergic reactions to
penicillin' above and 'Role of nonpenicillin regimens' above.)
● Jarisch-Herxheimer reaction – Treatment of syphilis may precipitate the Jarisch-

Herxheimer reaction, which may precipitate uterine contractions, preterm labor, and/or
nonreassuring fetal heart rate tracing in pregnant people treated in the second half of
pregnancy. Maternal discomfort is treated with supportive care and pregnancy
complications are managed by standard obstetric protocols. (See 'Potential complications
of treatment: Jarisch-Herxheimer reaction' above.)
● Maternal follow-up
6/19/22, 4:34 PM 4794
• Pregnant people treated for early syphilis should have a titer checked just before
treatment, since it is not uncommon for this titer to be higher than that of the initial
diagnostic titer due to elapsed time between diagnosis and therapy. The subsequent
frequency of monitoring is the same as in nonpregnant patients and depends upon the
stage of disease and presence of HIV coinfection. When monitoring nontreponemal
titers, the same test, preferably the rapid plasmin regain (RPR), should be performed
each time and at the same laboratory. (See 'Frequency of nontreponemal titers' above.)
• A fourfold increase in the nontreponemal titer after treatment is always abnormal. A

fourfold decline in the titer, equivalent to a change of two dilutions (eg, from 1:16 to 1:4
or from 1:32 to 1:8), is considered to be an acceptable response to syphilis therapy;
however, this can take months to achieve. A fall in maternal titers does not guarantee
that fetal treatment has been adequate. (See 'Interpretation of response to therapy
and diagnosis of treatment failure' above and 'Ultrasound examination' above.)
● Vertical transmission
• Frequency – The frequency of vertical transmission is higher with early stage than late
stage syphilis. Among people who acquire syphilis during pregnancy, the risk of vertical
transmission increases with increasing gestational age at acquisition of maternal
infection. (See 'Vertical transmission' above.)
• Prenatal diagnosis – Fetal infection should be suspected if there are characteristic

findings on ultrasound examination after 20 weeks of gestation in a patient with
untreated or inadequately treated syphilis. Hepatomegaly and placentomegaly are
early sonographic findings suggestive of congenital syphilis. Anemia, ascites, and
hydrops occur later in the course of fetal infection. An abnormal ultrasound is not
diagnostic of fetal infection and a normal ultrasound does not exclude fetal infection.
(See 'Prenatal (fetal) diagnosis' above.)
• Treatment – Maternal penicillin G benzathine treatment is curative for fetal infection in

most cases. Maternal treatment ≤30 days before delivery is a risk factor for congenital
infection. (See 'Fetal treatment and treatment failure' above.)
Use of UpToDate is subject to the Terms of Use.
REFERENCES
6/19/22, 4:34 PM 4794
1. United States Centers for Disease Control and Prevention. Sexually Transmitted Disease Sur
veillance 2019. https://www.cdc.gov/std/statistics/2019/default.htm (Accessed on August 0
2, 2021).
2. Bowen VB, McDonald R, Grey JA, et al. High Congenital Syphilis Case Counts among U.S.
Infants Born in 2020. N Engl J Med 2021; 385:1144.
3. Korenromp EL, Rowley J, Alonso M, et al. Global burden of maternal and congenital syphilis
and associated adverse birth outcomes-Estimates for 2016 and progress since 2012. PLoS
One 2019; 14:e0211720.
4. Newman L, Rowley J, Vander Hoorn S, et al. Global Estimates of the Prevalence and
Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic
Review and Global Reporting. PLoS One 2015; 10:e0143304.
5. Rac MW, Revell PA, Eppes CS. Syphilis during pregnancy: a preventable threat to maternal-
fetal health. Am J Obstet Gynecol 2017; 216:352.
6. Trivedi S, Williams C, Torrone E, Kidd S. National Trends and Reported Risk Factors Among
Pregnant Women With Syphilis in the United States, 2012-2016. Obstet Gynecol 2019;
133:27.
7. ROCKWELL DH, YOBS AR, MOORE MB Jr. THE TUSKEGEE STUDY OF UNTREATED SYPHILIS;
THE 30TH YEAR OF OBSERVATION. Arch Intern Med 1964; 114:792.
8. Sparling PF. Natural history of syphilis. In: Sexually Transmitted Diseases, Holmes KK, Mard
h PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.213.
9. Newman L, Kamb M, Hawkes S, et al. Global estimates of syphilis in pregnancy and

associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS
Med 2013; 10:e1001396.
10. Cheng JQ, Zhou H, Hong FC, et al. Syphilis screening and intervention in 500,000 pregnant
women in Shenzhen, the People's Republic of China. Sex Transm Infect 2007; 83:347.
11. Qin JB, Feng TJ, Yang TB, et al. Synthesized prevention and control of one decade for
mother-to-child transmission of syphilis and determinants associated with congenital
syphilis and adverse pregnancy outcomes in Shenzhen, South China. Eur J Clin Microbiol
Infect Dis 2014; 33:2183.
12. Royal College of Obstetricians and Gynaecologists. National evidence-based clinical guideli
nes. Antenatal care: Routine care for the healthy pregnant woman. www.rcog.org.uk/index.
asp?PageID=693 (Accessed on March 28, 2006).
13. Hossain M, Broutet N, Hawkes S. The elimination of congenital syphilis: a comparison of

the proposed World Health Organization action plan for the elimination of congenital
6/19/22, 4:34 PM 4794
syphilis with existing national maternal and congenital syphilis policies. Sex Transm Dis
2007; 34:S22.
14. Wolff T, Shelton E, Sessions C, Miller T. Screening for syphilis infection in pregnant women:
evidence for the U.S. Preventive Services Task Force reaffirmation recommendation
statement. Ann Intern Med 2009; 150:710.
15. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted
diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
16. American Academy of Pediatrics Committee on Fetus and Newborn and Amercian College
of Obstetricians and Gynecologists Committee on Obstetric Practice. Guidelines for Perinat
al Care, 8th, Kilpatrick SJ, Papile L (Eds), 2017.
17. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Syphilis Infection
in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation
Statement. JAMA 2018; 320:911.
18. Geusau A, Kittler H, Hein U, et al. Biological false-positive tests comprise a high proportion
of Venereal Disease Research Laboratory reactions in an analysis of 300,000 sera. Int J STD
AIDS 2005; 16:722.
19. Tinajeros F, Grossman D, Richmond K, et al. Diagnostic accuracy of a point-of-care syphilis
test when used among pregnant women in Bolivia. Sex Transm Infect 2006; 82 Suppl 5:v17.
20. Albright CM, Emerson JB, Werner EF, Hughes BL. Third-Trimester Prenatal Syphilis
Screening: A Cost-Effectiveness Analysis. Obstet Gynecol 2015; 126:479.
21. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment
Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
22. Rogozińska E, Kara-Newton L, Zamora JR, Khan KS. On-site test to detect syphilis in
pregnancy: a systematic review of test accuracy studies. BJOG 2017; 124:734.
23. Brandenburger D, Ambrosino E. The impact of antenatal syphilis point of care testing on
pregnancy outcomes: A systematic review. PLoS One 2021; 16:e0247649.
24. ACOG Committee Opinion No. 752: Prenatal and Perinatal Human Immunodeficiency Virus
Testing. Obstet Gynecol 2018; 132:e138.
25. Smikle MF, James OB, Prabhakar P. Biological false positive serological tests for syphilis in
the Jamaican population. Genitourin Med 1990; 66:76.
26. Boonchaoy A, Wongchampa P, Hirankarn N, Chaithongwongwatthana S. Performance of
Chemiluminescent Microparticle Immunoassay in Screening for Syphilis in Pregnant
Women from Low-Prevalence, Resource-Limited Setting. J Med Assoc Thai 2016; 99:119.
6/19/22, 4:34 PM 4794
27. Wang KD, Xu DJ, Su JR. Preferable procedure for the screening of syphilis in clinical
laboratories in China. Infect Dis (Lond) 2016; 48:26.
28. Mmeje O, Chow JM, Davidson L, et al. Discordant Syphilis Immunoassays in Pregnancy:
Perinatal Outcomes and Implications for Clinical Management. Clin Infect Dis 2015;
61:1049.
29. Henrich TJ, Yawetz S. Impact of age, gender, and pregnancy on syphilis screening using the
Captia Syphilis-G assay. Sex Transm Dis 2011; 38:1126.
30. Wellinghausen N, Dietenberger H. Evaluation of two automated chemiluminescence

immunoassays, the LIAISON Treponema Screen and the ARCHITECT Syphilis TP, and the
Treponema pallidum particle agglutination test for laboratory diagnosis of syphilis. Clin
Chem Lab Med 2011; 49:1375.
31. Williams JEP, Bazan JA, Turner AN, et al. Reverse Sequence Syphilis Screening and
Discordant Results in Pregnancy. J Pediatr 2020; 219:263.
32. Lin JS, Eder ML, Bean SI. Screening for Syphilis Infection in Pregnant Women: Updated
Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA
2018; 320:918.
33. Ray JG. Lues-lues: maternal and fetal considerations of syphilis. Obstet Gynecol Surv 1995;
50:845.
34. Wendel GD Jr, Sheffield JS, Hollier LM, et al. Treatment of syphilis in pregnancy and
prevention of congenital syphilis. Clin Infect Dis 2002; 35:S200.
35. Zhu L, Qin M, Du L, et al. Maternal and congenital syphilis in Shanghai, China, 2002 to 2006.
Int J Infect Dis 2010; 14 Suppl 3:e45.
36. Hawkes S, Matin N, Broutet N, Low N. Effectiveness of interventions to improve screening
for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis 2011;
11:684.
37. Nathan L, Bawdon RE, Sidawi JE, et al. Penicillin levels following the administration of
benzathine penicillin G in pregnancy. Obstet Gynecol 1993; 82:338.
38. Weeks JW, Myers SR, Lasher L, et al. Persistence of penicillin G benzathine in pregnant
group B streptococcus carriers. Obstet Gynecol 1997; 90:240.
39. Wendel GD Jr, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious
infections during pregnancy. N Engl J Med 1985; 312:1229.
40. WHO GUIDELINES FOR THE TREATMENT OF TREPONEMA PALLIDUM (SYPHILIS) http://apps.
who.int/iris/bitstream/handle/10665/249572/9789241549806-eng.pdf;jsessionid=AF41E61D
F3856FC93F39BD8D2466AC64?sequence=1 (Accessed on March 30, 2022).
6/19/22, 4:34 PM 4794
41. Zhou P, Gu Z, Xu J, et al. A study evaluating ceftriaxone as a treatment agent for primary
and secondary syphilis in pregnancy. Sex Transm Dis 2005; 32:495.
42. Klein VR, Cox SM, Mitchell MD, Wendel GD Jr. The Jarisch-Herxheimer reaction complicating
syphilotherapy in pregnancy. Obstet Gynecol 1990; 75:375.
43. Myles TD, Elam G, Park-Hwang E, Nguyen T. The Jarisch-Herxheimer reaction and fetal
monitoring changes in pregnant women treated for syphilis. Obstet Gynecol 1998; 92:859.
44. Gudjónsson H, Skog E. The effect of prednisolone on the Jarisch-Herxheimer reaction. Acta
Derm Venereol 1968; 48:15.
45. Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment
with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335:311.
46. Coxon RE, Fekade D, Knox K, et al. The effect of antibody against TNF alpha on cytokine
response in Jarisch-Herxheimer reactions of louse-borne relapsing fever. QJM 1997; 90:213.
47. Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-
Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.
48. Remick DG, Negussie Y, Fekade D, Griffin G. Pentoxifylline fails to prevent the Jarisch-
Herxheimer reaction or associated cytokine release. J Infect Dis 1996; 174:627.
49. FIUMARA NJ, FLEMING WL, DOWNING JG, GOOD FL. The incidence of prenatal syphilis at
the Boston City Hospital. N Engl J Med 1952; 247:48.
50. Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the University of Miami/Jackson
Memorial Medical Center experience, 1986-1988. Obstet Gynecol 1989; 74:687.
51. FIUMARA NJ. Congenital syphilis in Massachusetts. N Engl J Med 1951; 245:634.
52. Giakoumelou S, Wheelhouse N, Cuschieri K, et al. The role of infection in miscarriage. Hum
Reprod Update 2016; 22:116.
53. Lago EG, Vaccari A, Fiori RM. Clinical features and follow-up of congenital syphilis. Sex
Transm Dis 2013; 40:85.
54. Mascola L, Pelosi R, Blount JH, et al. Congenital syphilis. Why is it still occurring? JAMA 1984;
252:1719.
55. Harter C, Benirschke K. Fetal syphilis in the first trimester. Am J Obstet Gynecol 1976;
124:705.
56. Hollier LM, Harstad TW, Sanchez PJ, et al. Fetal syphilis: clinical and laboratory
characteristics. Obstet Gynecol 2001; 97:947.
57. Gomez GB, Kamb ML, Newman LM, et al. Untreated maternal syphilis and adverse
outcomes of pregnancy: a systematic review and meta-analysis. Bull World Health Organ
6/19/22, 4:34 PM 4794
2013; 91:217.
58. Qin J, Yang T, Xiao S, et al. Reported estimates of adverse pregnancy outcomes among
women with and without syphilis: a systematic review and meta-analysis. PLoS One 2014;
9:e102203.
59. Harman NB. Staying the Plague, Methuen & Co., LTD, London 1917.
60. INGRAHAM NR Jr. The value of penicillin alone in the prevention and treatment of
congenital syphilis. Acta Derm Venereol Suppl (Stockh) 1950; 31:60.
61. Sheffield JS, Sánchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for
syphilis during pregnancy. Am J Obstet Gynecol 2002; 186:569.
62. Fiumara NJ. Syphilis in newborn children. Clin Obstet Gynecol 1975; 18:183.
63. Rubin R. Why Are Mothers Still Passing Syphilis to Their Babies? JAMA 2019; 321:729.
64. Slutsker JS, Hennessy RR, Schillinger JA. Factors Contributing to Congenital Syphilis Cases -
New York City, 2010-2016. MMWR Morb Mortal Wkly Rep 2018; 67:1088.
65. David M, Hcini N, Mandelbrot L, et al. Fetal and neonatal abnormalities due to congenital
syphilis: A literature review. Prenat Diagn 2022; 42:643.
66. Rac MW, Bryant SN, McIntire DD, et al. Progression of ultrasound findings of fetal syphilis
after maternal treatment. Am J Obstet Gynecol 2014; 211:426.e1.
67. Blencowe H, Cousens S, Kamb M, et al. Lives Saved Tool supplement detection and
treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal
mortality. BMC Public Health 2011; 11 Suppl 3:S9.
Topic 4794 Version 74.0
6/19/22, 4:34 PM 4794
GRAPHICS
Screening and diagnosis of syphilis in pregnant women without prior syphilis
STI: sexually transmitted infection.
* The initial type of screening test (treponemal versus nontreponemal) is typically dictated by the clinical lab
6/19/22, 4:34 PM 4794
¶ Nontreponemal tests include the rapid plasma reagin (RPR), the Venereal Disease Research Laboratory (VD
toluidine red unheated serum test (TRUST).
Δ Treponemal tests include the fluorescent treponemal antibody absorption (FTA-ABS), the Treponema pallid
agglutination (TPPA), the T. pallidum enzyme immunoassay (TP-EIA), or chemiluminescence immunoassay (C
treponemal tests target different antigens.
◊ Refer to the topic that discusses syphilis and pregnancy for treatment regimens.
§ A reactive low titer nontreponemal screening test can be considered a transient biologic false-positive resu
if the confirmatory treponemal test is negative and the patient is asymptomatic and at low risk of acute syph
nontreponemal test results can also be related to an acute event, such as an acute febrile illness or recent im
abnormalities attributed to these conditions are usually transitory and typically last for 6 months or less.
¥ If at 28 to 32 weeks gestation a screening nontreponemal test (eg, RPR) is reactive and the confirmatory tr
FTA-ABS) is nonreactive, treatment is usually the best option rather than repeating a confirmatory treponem
weeks. If at 28 to 32 weeks a screening treponemal test is reactive and the confirmatory nontreponemal tes
second treponemal test that targets different antigens should be performed; if positive, serology is consiste
if negative, syphilis is unlikely. However, if there is diagnostic uncertainty (eg, a second treponemal test cann
the setting of pregnancy, we prefer to treat.
‡ Testing performed at delivery is used to help inform the pediatrician regarding screening/treatment of the
of the mother at delivery does not prevent transmission.
Graphic 116084 Version 4.0
6/19/22, 4:34 PM 4794
Clinical manifestation of syphilis
Stage Clinical manifestations
Primary syphilis Single painless ulcer (chancre) at site of inoculation, regional

adenopathy
Secondary syphilis Rash (disseminated and/or involving the palms and soles), fever,
malaise, mucocutaneous lesions, hepatitis, arthritis,
glomerulonephritis, condyloma lata, pharyngitis, alopecia
Latent syphilis Asymptomatic
Early latent (<1 year after

initial infection)
Late latent (>1 year after

initial infection)
Tertiary (late) syphilis
Gummatous disease Granulomatous disease of the skin and subcutaneous tissues, bones,
or viscera
Cardiovascular disease Aortic aneurysm, aortic insufficiency
Central nervous system Tabes dorsalis, Argyll-Robertson pupils, paresis, seizures, subtle
disease (neurosyphilis) psychiatric manifestations, dementia. May be asymptomatic.
Neurosyphilis (can occur at any time during the course of infection)
Early Asymptomatic meningitis, symptomatic meningitis, or, less

commonly, meningovascular disease (ie, meningitis and stroke).
Vision or hearing loss with or without concomitant meningitis may
also be present, and ocular/otologic syphilis is treated as
neurosyphilis.
Late Most common forms involve the brain and spinal cord (dementia
[general paresis] and tabes dorsalis).
6/19/22, 4:34 PM 4794
Treatment of syphilis in pregnancy
Stage of syphilis Treatment
Primary/secondary/early Penicillin G benzathine (Bicillin L-A) 2.4 million units IM in a single dose
latent (usually administered as 1.2 million units in each buttock)*
Late Penicillin G benzathine (Bicillin L-A) 2.4 million units IM once weekly
latent/tertiary/unknown (usually administered as 1.2 million units in each buttock) for 3 weeks (7.2
duration million units total dose)¶
Neurosyphilis (including Aqueous crystalline penicillin G (intravenous) 18 to 24 million units per

ocular syphilis)Δ day, administered as 3 to 4 million units IV every 4 hours or as a
continuous infusion over 24 hours for 10 to 14 days
OR
Penicillin G procaine 2.4 million units IM once daily (usually administered

as 1.2 million units in each buttock) plus probenecid 500 mg PO 4 times
daily, both for 10 to 14 days
Post-exposure Penicillin G benzathine (Bicillin L-A) 2.4 million units IM in a single dose
prophylaxis (usually administered as 1.2 million units in each buttock)
Pregnant women are treated with the penicillin regimen appropriate for their stage of infection.
Parenteral (IM or IV) penicillin G is the only therapy with documented safety and efficacy for both
mother and fetus during pregnancy. Pregnant women with a history of penicillin allergy should
be desensitized and treated with penicillin. Refer to the relevant topic review for further guidance
on management of pregnant patients with penicillin allergy.
If penicillin desensitization is not possible for treatment of early syphilis (primary, secondary, or
latent <2 years), the World Health Organization (WHO) suggests using, with caution,
erythromycin 500 mg 4 times daily for 14 days, ceftriaxone 1 g IM once daily for 10 to 14 days, or
azithromycin 2 g once orally (when local susceptibility to azithromycin is likely). If penicillin
desensitization is not possible for treatment of late syphilis, the WHO recommends treatment
with erythromycin 500 mg orally 4 times daily for 30 days. Macrolides (eg, erythromycin) do not
completely cross the placental barrier; therefore, the WHO also recommends that infants born to
women treated with non-penicillin regimens receive a 10 to 15 day course of parenteral penicillin
treatment.
IM: intramuscular; IV: intravenous; PO: oral.
* If serologic failure is detected at follow-up and additional follow-up cannot be assured, consider
retreating with penicillin G benzathine 2.4 million units IM once weekly for 3 weeks. Prompt
cerebrospinal fluid examination is recommended.
¶ If a dose is missed for more than 14 days, then the full 3 dose course of therapy should be
restarted.
Δ Penicillin G benzathine 2.4 million units IM once per week for up to 3 weeks may be administered
after completion of IV penicillin G treatment to provide a comparable total duration of therapy as
6/19/22, 4:34 PM 4794
latent syphilis.
Data from:
1. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment
guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
2. World Health Organization guidelines for treatment of Treponema pallidum (syphilis), 2016.
http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf?ua=1 (Accessed on August 15, 2018).
6/19/22, 4:34 PM 4794
Classification of allergic reactions (Gell and Coombs)
Clinical
Type Description Mechanism
features
I Anaphylactic, Antigen exposure causes release of vasoactive Anaphylaxis

immediate-type substances, such as histamine, prostaglandins,
Immediate Angioedema
hypersensitivity and leukotrienes from mast cells or basophils. This
reaction
response is usually, but not always, IgE- Bronchospasm
(30 to 60
dependent. Urticaria
min)
(hives)
Accelerated
reaction (1
to 72
hours)
II Antibody- An antigen or hapten that is intimately associated Hemolytic

dependent with a cell binds to antibody, leading to cell or anemia
cytotoxicity tissue injury.
Interstitial
nephritis
III Immune Damage is caused by formation or deposition of Serum

complex antigen-antibody complexes in vessels or tissue. sickness
disease
IV Cell-mediated Antigen exposure sensitizes T cells, which then Contact

or delayed mediate tissue injury. dermatitis
hypersensitivity
V Uncertain, but probably involving T cell Maculopapular

cytotoxicity. rash
(>72 hours)
IgE: immunoglobulin E.
Adapted from: Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy
1988; 18:515.
6/19/22, 4:34 PM 4794
Clinical manifestations of early congenital syphilis*
Gestational/perinatal
Stillbirth
Prematurity
Birth weight <2500 g
Nonimmune hydrops fetalis
Placenta Large, thick, pale (send for pathologic/histologic

evaluation)
Umbilical cord Inflamed with abscess-like foci of necrosis within Wharton's

jelly, centered around the umbilical vessels (necrotizing
funisitis); barber-pole appearance (send for
pathologic/histologic evaluation)
Systemic
Fever May be more prominent in infants born to mothers who

are affected late in pregnancy and whose serology is
negative at delivery
Hepatomegaly Splenomegaly occurs in approximately one-half of patients

with hepatomegaly—isolated splenomegaly does not occur
Generalized lymphadenopathy May be as large as 1 cm; generally nontender and firm
Failure to thrive
Edema Due to anemia/hydrops fetalis, nephrotic syndrome,

malnutrition
Mucocutaneous
Syphilitic rhinitis ("snuffles") Can be an early feature, developing after the first week of
life; contains spirochetes and is infectious (use contact
precautions)
Maculopapular rash Usually appears one to two weeks after rhinitis. Oval
lesions, initially red or pink and then coppery brown; may
be associated with superficial desquamation or scaling,
particularly on the palms or soles; more common on the
buttocks, back, posterior thighs, and soles; contains
spirochetes and is infectious (use contact precautions).
Vesicular rash (pemphigus May be present at birth, most often develops in first four
syphiliticus) weeks; widely disseminated; vesicular fluid contains
spirochetes and is infectious (use contact precautions)
Condylomata lata Single or multiple, flat, wartlike, moist lesions around the
6/19/22, 4:34 PM 4794
mouth, nares, and anus and other areas of the skin where
there is moisture or friction; lesions contain spirochetes
and are infectious (use contact precautions); frequently
present without other signs of infection
Jaundice Hyperbilirubinemia secondary to syphilitic hepatitis and/or

hemolysis
Hematologic
Anemia Newborn period: Hemolytic (Coomb's test [direct
antiglobulin test] negative); may persist after effective
treatment
After one month of age: May be chronic and nonhemolytic
Thrombocytopenia May be associated with bleeding or petechiae; can be the

only manifestation of congenital infection
Leukopenia
Leukocytosis
Musculoskeletal
Pseudoparalysis of Parrot Lack of movement of an extremity because of pain
associated with bone lesion; affects upper extremities
more often than lower; usually unilateral; rarely present at
birth; poorly correlated with radiographic abnormalities
Radiographic abnormalities: Most frequent abnormality in untreated early congenital

syphilis; not usually clinically discernible; typically multiple
and symmetric
Periostitis Irregular periosteal thickening; usually present at birth,

but may appear in the first few weeks of life
Wegner sign Metaphyseal serration or "sawtooth metaphysis"
Wimberger sign Demineralization and osseous destruction of the upper

medial tibial
Neurologic
CSF abnormalities Reactive CSF VDRL; elevated CSF white blood cell count;
elevated CSF protein
Acute syphilitic leptomeningitis Onset during the first year of life, usually between 3 and 6
months; presentation similar to bacterial meningitis but
CSF findings more consistent with aseptic meningitis
(mononuclear predominance); responds to penicillin
therapy
Chronic meningovascular syphilis Onset toward the end of the first year; hydrocephalus;
cranial nerve palsies; intellectual/neurodevelopmental
6/19/22, 4:34 PM 4794
deterioration; cerebral infarction; protracted course
Miscellaneous
Pneumonia/pneumonitis/respiratory Complete opacification of both lung fields on chest
distress radiograph
Nephrotic syndrome Usually occurs at two to three months of age and

manifests with generalized edema and ascites
CSF: cerebrospinal fluid; VDRL: Venereal Disease Research Laboratory test.
* All of these findings may occur in other congenital infections; none is specific for congenital
syphilis.
Data from:
1. Ingall D, Sanchez PJ, Baker CH. Syphilis. In: Infectious Diseases of the Fetus and Newborn infant, 6th edition,
Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.545.
2. Dobson SR, Sanchez PJ. Syphilis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th, Cherry JD,
Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.1761.
3. Woods CR. Syphilis in children: congenital and acquired. Semin Pediatr Infect Dis 2005; 16:245.
4. Saloojee H, Velaphi S, Goga Y, et al. The prevention and management of congenital syphilis: an overview and
recommendations. Bull World Health Organ 2004; 82:424.
5. Chakraborty R, Luck S. Syphilis is on the increase: the implications for child health. Arch Dis Child 2008; 93:105.
6. Rawstron SA. Treponema pallidum (Syphilis). In: Principles and Practice of Pediatric Infectious Diseases, 3rd edition,
Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone Elsevier, Philadelphia 2008. p.930.
6/19/22, 4:34 PM 4794
Syphilis of the placenta
(A) Chronic villitis.
(B) Onion skin placental villi.
Courtesy of Drucilla J Roberts, MD.
6/19/22, 4:34 PM 4794
Contributor Disclosures
Errol R Norwitz, MD, PhD, MBA Patent Holder: Bayer [Prediction test for preeclampsia].
Consultant/Advisory Boards: Cognitive Care/Early Detect[AI platform for early risk detection and
quantification];Illumina [Minimally invasive genetic testing for fetal and pregnancy-related disorders].
Other Financial Interest: NICHD [Board of Scientific Counselors]. All of the relevant financial relationships
listed have been mitigated. Charles B Hicks, MD No relevant financial relationship(s) with ineligible
companies to disclose. Charles J Lockwood, MD, MHCM No relevant financial relationship(s) with
ineligible companies to disclose. Jeanne Marrazzo, MD, MPH, FACP, FIDSA Equity Ownership/Stock
Options: Osel Inc [Vaginal infections]. Grant/Research/Clinical Trial Support: BD Diagnostics [Vaginal
infections, STI]. Consultant/Advisory Boards: Gilead [HIV];Merck [HIV]. All of the relevant financial
relationships listed have been mitigated. Vanessa A Barss, MD, FACOG No relevant financial
relationship(s) with ineligible companies to disclose. Jennifer Mitty, MD, MPH No relevant financial
relationship(s) with ineligible companies to disclose.
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are
addressed by vetting through a multi-level review process, and through requirements for references to be
provided to support the content. Appropriately referenced content is required of all authors and must
conform to UpToDate standards of evidence.
Conflict of interest policy

Syphilis in Pregnancy

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Syphilis in Pregnancy

Uploaded by

Copyright:

Available Formats

6/19/22, 4:34 PM 4794

Official reprint from UpToDate®

Syphilis is a systemic infection caused by the spirochete Treponema pallidum. Infection is of

● (See "Congenital syphilis: Clinical features and diagnosis".)

MATERNAL ACQUISITION OF INFECTION

MATERNAL CLINICAL MANIFESTATIONS

Universal antepartum screening is widely recommended because screening followed by

Candidates and timing of initial and repeat screening

● All pregnant people: screen at the first prenatal encounter

● Specific treponemal tests include fluorescent treponemal antibody absorption (FTA-ABS),

The diagnostic interpretation of syphilis serology, including interpretation of testing in patients

False-positive serologic tests in pregnancy

● Prevalence – Biologic false-positive nontreponemal and treponemal results are relatively

● Follow-up after delivery – All patients with biologic false-positives attributed to

● Secondary syphilis — Secondary syphilis is a disseminated systemic process that occurs

● Tertiary (late) syphilis — Tertiary syphilis is infrequently diagnosed and is characterized

Preferred regimen: penicillin

● The appropriate penicillin G benzathine regimen depends on the stage of disease (

Treatment of primary, secondary, or early latent disease and post-exposure prophylaxis

Treatment of late latent and tertiary disease

Treatment of neurosyphilis — Treatment of neurosyphilis is parenteral and typically requires

Penicillin allergy is reported by 5 to 10 percent of pregnant people [39]; however, serious

Referral — Patients who report symptoms suggestive of a past immediate allergy to a

Desensitization — It is strongly recommended that desensitizations be performed by

Role of nonpenicillin regimens — During pregnancy, nonpenicillin antibiotic regimens used

- Erythromycin 500 mg orally four times daily for 14 days, or

- Aqueous benzyl penicillin 100,000 to 150,000 U/kg/day intravenously for 10 to 15

POTENTIAL COMPLICATIONS OF TREATMENT: JARISCH-HERXHEIMER

● Signs and symptoms – Clinical manifestations include an acute febrile reaction

Management is supportive care (eg, antipyretics, intravenous fluids).

● Complications – The Jarisch-Herxheimer reaction may precipitate uterine contractions,

● Role of premedication – The authors do not premedicate patients. Premedication with

Premedication with acetaminophen or meptazinol may reduce the severity or duration of

POST-TREATMENT MATERNAL FOLLOW-UP

Interpretation of response to therapy and diagnosis of treatment failure

● A fourfold increase in the nontreponemal titer after treatment is evidence of treatment

A decline in maternal nontreponemal serologic titers following treatment does not

nonpregnant patients, an adequate response to therapy is expected by 12 months for patients

POTENTIAL ADVERSE PREGNANCY OUTCOMES

Pathogenesis of congenital infection — T. pallidum readily infects the placenta. Transplacental

Factors influencing frequency of vertical transmission — In two systematic reviews, 15 and

● Maternal acquisition of infection later rather than earlier in gestation – The

● Failure to appropriately identify and treat maternal infection – Reviews of congenital

• Lack of third-trimester rescreening in high-risk patients

• Lack of appropriate follow-up and treatment

● Growth restriction (14 percent)

● Hydrops (12 percent)

• Skin edema 7 percent, pericardial effusion 2 percent, ascites 19 percent

● Polyhydramnios (11 percent), oligohydramnios (9 percent)

Congenital infection has been diagnosed in 1 to 2 percent of offspring of mothers adequately

In an observational series of 43 treatment failures, the following characteristics were more

● High nontreponemal titer at treatment and delivery

Ultrasound examination — At least one ultrasound examination after 20 weeks of gestation

SOCIETY GUIDELINE LINKS

INFORMATION FOR PATIENTS

● Basics topic (see "Patient education: Congenital syphilis (The Basics)")

SUMMARY AND RECOMMENDATIONS

• All pregnant people: screen at the first prenatal encounter

• Pregnant people at high risk of infection: repeat screening at 28 to 32 weeks and at

● False-positive screening tests – False-positive screening tests may be more common in

● Treatment – Penicillin G benzathine is the standard for the treatment of syphilis

• Penicillin G benzathine therapy is effective for treating maternal disease, preventing

• The appropriate penicillin G benzathine regimen depends on the stage of disease (